Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives

Journal of Medicinal Chemistry

Volumn 41, Issue 4, 1998, Pages 640-649

  Tamura, Yoshinori ^a   Watanabe, Fumihiko ^a   Nakatani, Takuji ^a   Yasui, Ken ^a   Fuji, Masahiro ^a   Komurasaki, Tadafumi ^a   Tsuzuki, Hiroshige ^a   Maekawa, Ryuji ^a   Yoshioka, Takayuki ^a   Kawada, Kenji ^a   Sugita, Kenji ^a   Ohtani, Mitsuaki ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 2 [[4 [2 [4 (METHYLMERCAPTO)PHENYL] 2H TETRAZOL 5 YL]BENZENESULFONYL]AMINO]BUTANOIC ACID; [(4 BIPHENYLYLSULFONYL)AMINO] N HYDROXY 3 PHENYLPROPIONAMIDE; ANTINEOPLASTIC AGENT; COLLAGENASE INHIBITOR; ENZYME INHIBITOR; GELATINASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; N SULFONYLAMINO ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH INHIBITION; LUNG CARCINOMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; GELATINASES; HUMANS; INDICATORS AND REAGENTS; KINETICS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 14444272508     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9707582     Document Type: Article

References (36)

1. Cossins, J.; Dudgeon, T. J.; Catlin, G.; Gearing, A. J. H.; Clements, J. M. Identification of MMP-18, a Putative Novel Human Matrix Metalloproteinase. Biochim. Biophys. Res. Commun. 1996, 228, 494-498.
2. Pendas, A. M.; Knauper, V.; Puente, X. S.; Llano, E.; Mattel, M. G.; Apote, S.; Murphy, G.; Lopez-Otin, C. Identification and Characterization of a Novel Human Matrix Metalloproteinase with Unique Structure Characteristic, Chromosomal Location, and Tissue Distribution. J. Biol. Chem. 1997, 272, 4281-4286.
3. Lovejoy, B.; Cleasby, A.; Hassell, A. M.; Longley, K.; Luther, M. A.; Weigl, D.; McGeehan, G.; McElroy, A. B.; Drewry, D.; Lambert, M. H.; Jordan, S. R. Structure of the Catalytic Domain of Fibroblast Collagenase Complexed with an Inhibitor. Science 1994, 263, 375-377.
4. Bode, W.; Reinemer, P.; Huber, R.; Kleine, T.; Schnierer, S.; Tschesche, H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBOJ. 1994, 13, 1263-1269.
5. Browner, M. P.; Smith, W. W.; Castelhano, A. L. Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases. Biochemistry 1995, 34, 6602-6610.
6. Gooley, P. R.; O'Connell, J. F.; Marcy, A. L; Cuca, G. C.; Salowe, S. P.; Bush, B. L.; Hermes, J. D.; Esser, C. K.; Hagmann, W. K.; Springer, J. P.; Johnson, B. A. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Struct, Biol. 1994, 1, 111-118.
7. r 72,000 and 92,000 Type W Collagenases in Human Skin Cancers by in Situ Hybridization. Cancer Res. 1992, 52, 1336-1341.
8. Walakovits, L. A.; Moore, V. L.; Bhardwaj, N.; Gallick, G. S.; Lark, M. W. Detection of Stromelysin and Collagenase in Synovial Fluid from Patients with Rheumatoid Arthritis and Posttraumatic Knee Injury. Arthritis Rheumatism 1992, 35, 35-42.
9. Gijbels, K.; Masure, S.; Carton, H.; Opdenakker, G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 1992, 41, 29-34.
10. Ries, C. L.; Petrides, P. E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem. Hoppe-Seyler 1995, 376, 345-355.
11. Stetler-Stevenson, W. G.; Aznavoorian, S.; Liotta, L. A. Tumor cell interactions with the extracellular-matrix during invasion and metastasis. Annu. Rev. Cell. Biol. 1993, 9, 541-573.
12. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. Cancer Metastasis and Angiogenesis: An imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
13. Paul-Beckett, R.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Discovery Today 1996, 1, 16-26.
14. Davidson, A. H.; Drummndo, A. H.; Galloway, W. A.; Whittaker, M. The inhibition of metalloproteinase enzymes. Chem. Ind. 1997, 7, 258-261.
15. Beckett, R. P. Recent advances in the field of matrix metalloproteinase inhibitors. Exp. Opin. Ther. Pat. 1996, 6, 1305-1315.
16. Rasmussen, H. S. Preclinical and early clinical data with Batimastat and Marimastat: Two novel matrix metalloproteinase inhibitors. Protease Inhibitors; International Business Communication Inc.: Southborough, MA, 1997; Chapter 4.2.
17. Galardy, R. E. Galardin. Antiinflammatory Protease Inhibitor. Drugs Future 1993, 18, 1109-1111.
18. Aral, L; Muramatsu, I. A Simple and Convenient Method for Esterification of Tryptophan and Other Amino Acids. J. Org. Chem. 1983, 48, 121-123.
19. (a) Suter, C. M. Studies in the Diphenyl Ether Series. II. Preparation and Structure of Some Sulfonic Acids and Related Derivatives. J. Am. Chem. Soc. 1931, 53, 1112-1116.
20. (b) Dart, E. C.; Holt, G. Interaction of the Isomeric Chlorosulfonylbenzoyl Chlorides and Benzene, under the Influence of Aluminium Chloride. J. Chem. Soc, Perkin Trans. 1 1974, 12, 1403-1406.
21. Hamada, T.; Yonemitsu, O. An Improved Synthesis of Arylsulfonyl Chlorides from Aryl Halides. Synthesis 1986, 4, 852-854.
22. Miyaura, N.; Yanagi, T.; Suzuki, A. The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
23. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457-2483.
24. Sonogashira, K.; Tohda, Y.; Hagihara, N. A Convenient Synthesis of Acetylenes: Catalytic Substitutions of Acetylenic Hydrogen with Bromoalkenes, lodoarenes, and Bromopyridines. Tetrahedron Lett. 1975, 50, 4467-4470.
25. Takahashi, S.; Kuroyama, Y.; Sonogashira, K.; Hagihara, N. A Convenient Synthesis of Ethynylarenes and Diethynylarenes. Synthesis 1980, 8, 627-630.
26. Ito, S.; Tanaka, Y.; Kakehi, A.; Hondo, K. A New Synthesis of 2,5-Disubstituted Tetrazoles via 1,5-Dipolar Cyclization. Chem. Lett. 1973, 10, 1071-1072.
27. Hodgson, J. Remodeling MMPIs. Matrix metalloproteinase inhibitors will be approved as drugs, probably this year, but questions remain concerning their specificity, bioavailability, and potential long-term toxicity. Biotechnology 1995, 13, 554-557.
28. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Application to Drug Design. Chem. Rev. (Washington, D.C.) 1997, 97, 1359-1472.
29. He, J. X.; Cody, W. L.; Doherty, A. M. An Efficient Preparation of the Pseudopeptide Endothelin-B Receptor Selective Antagonist BQ-788. J. Org. Chem. 1995, 60, 8262-8266.
30. 3 to about 0.4 unit/ mL and inhibitor was diluted in DMSO to various concentrations before use, unless otherwise stated.
31. 4-Fluoro-7-sulfamoylbenzofurazan (ABD-F) was purchased from Dojindo Laboratories.
32. 3was purchased from Bachern.
33. 2 and Bz-Ala-AJa-Leu-pNA were purchased from Peptide Institute.
34. Female BDF1 (7-9 weeks old) and female athymic BALB/c-nu/ nu mice (8-10 weeks old) used in this study were purchased from Nihon SLC (Shizuoka, Japan) and Clea Japan Inc. (Tokyo, Japan), respectively.
35. Lewis mutine lung carcinoma were obtained from the National Cancer Institute (NCI, Rock ville, MD) and maintained by serial sc transplantation as a tumor fragment. Ma44 human lung squamous cell carcinoma was kindly supplied by Dr. Komiya (Habikino Hospital, Osaka, Japan) and maintained by in vitro passage using Eagle's MEM (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10% fetal calf serum (Gibco BRM, Rockville, MD). Production of type IV collagenases in these cell lines was confirmed by gelatin zymography.
36. Kitamura, Y.; Okamoto, S.; Uchida, N.; Yamaguchi, K.; Matsumoto, K. Effect of Androgen Depletion on Growth and Androgen Dependency of Shionogi Carcinoma 115. Cancer Res. 1978, 38, 4711-4716.